NTHI 주가 차트
NTHI 수입
NeOnc Technologies Holdings Inc
$5.5
0.73%
$0.04
종가: May 15, 16:00:00 GMT-4
$5.5
0%
$0
애프터마켓: May 15, 20:00:00 GMT-4
뒤로
NeOnc Technologies Holdings Inc (NTHI) 수입
Earnings FAQ
NTHI의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
NeOnc Technologies Holdings Inc NTHI의 지난 분기 매출 실적은 어땠나요?
NeOnc Technologies Holdings Inc의 매출 추정치는 얼마인가요?
NeOnc Technologies Holdings Inc의 수익 품질 점수는 얼마인가요?
NeOnc Technologies Holdings Inc는 언제 수익을 보고하나요?
NeOnc Technologies Holdings Inc의 예상 수익은 얼마인가요?
NeOnc Technologies Holdings Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$5.46
시가
$5.62
일일 범위
$5.33 - $5.7
52주 범위
$3.2 - $12.99
거래량
52.0K
평균 거래량
65.6K
배당수익률
--
EPS(TTM)
-3.20
시가총액
$137.0M
NTHI란 무엇인가요?
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Calabasas, California and currently employs 5 full-time employees. The company went IPO on 2025-03-26. The firm is focused on establishing treatments for intracranial malignancies, such as aggressive cancers located in the brain. The company is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company is developing novel drug delivery methods to be used in combination with novel drug candidates. The firm has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (POH) which is administered to brain cancer patients via intranasal delivery. NEO212 is a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, and others).
